2025
SJR Q2
JCR Q4 · 1,9
64 matched articles
SCIE
Journal detail
Oncology (Switzerland)
- Publisher
- S. Karger AG
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
0030241414230232
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,596
- Quartile Q2
- H-Index 112
- Cites/doc 1,99
- Docs (3y) 262
- Cites (3y) 532
Clarivate
Web of Science · JCR · 2025
- JCR Q Q4
- JIF 1,9
- 5Y JIF 2,2
- JCI 0,36
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q3
- Medicine (miscellaneous) Q2
- Oncology Q3
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
WoS categories
- Oncology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q4 | 0,596 | 1,9 | 2,2 | 0,36 | Q4 | 112 |
| 2024 | Q2 | Q4 | 0,747 | 1,8 | 2,4 | 0,45 | Q3 | 110 |
| 2023 | Q2 | Q3 | 0,832 | 2,5 | 2,5 | 0,54 | Q3 | 110 |
| 2022 | Q2 | Q3 | 0,856 | 3,5 | 3,2 | 0,61 | Q3 | 110 |
| 2021 | Q2 | Q3 | 0,785 | 3,7 | 3,5 | 0,6 | Q3 | 110 |
| 2020 | Q1 | Q4 | 0,987 | 2,9 | 3 | 0,63 | Q3 | 110 |
| 2019 | Q1 | Q3 | 0,932 | 2,6 | 2,3 | 0,63 | Q3 | 110 |
| 2018 | — | Q3 | — | 2,3 | 2,1 | 0,6 | Q3 | — |
| 2017 | Q1 | — | 1,013 | — | — | — | — | 110 |
| 2016 | Q1 | Q3 | 0,962 | 2,3 | 2,4 | — | — | 110 |
| 2015 | Q1 | Q3 | 0,993 | 2,2 | 2,5 | — | — | 110 |
| 2014 | Q1 | Q3 | 1,152 | 2,4 | 2,6 | — | — | 110 |
| 2013 | Q1 | Q3 | 1,348 | 2,6 | 2,7 | — | — | 110 |
| 2012 | Q1 | Q3 | 1,137 | 2,2 | 2,5 | — | — | 110 |
| 2011 | Q1 | Q3 | 1,315 | 2,3 | 2,4 | — | — | 110 |
| 2010 | Q1 | Q2 | 1,345 | 2,5 | 2,7 | — | — | 110 |
| 2009 | — | Q3 | — | 2,1 | 2,4 | — | — | — |
| 2008 | — | Q4 | — | 1,3 | 2,3 | — | — | — |
| 2007 | — | Q3 | — | 2,4 | 2,4 | — | — | — |
| 2006 | — | Q3 | — | 2,3 | — | — | — | — |
| 2005 | — | Q3 | — | 2 | — | — | — | — |
| 2004 | — | Q3 | — | 2,1 | — | — | — | — |
| 2003 | — | Q2 | — | 2,4 | — | — | — | — |
| 2002 | — | Q2 | — | 2,3 | — | — | — | — |
| 2001 | — | Q2 | — | 3 | — | — | — | — |
| 2000 | — | Q2 | — | 2,6 | — | — | — | — |
| 1999 | — | Q2 | — | 2,7 | — | — | — | — |
| 1998 | — | Q1 | — | 2,9 | — | — | — | — |
| 1997 | — | Q2 | — | 2,1 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q4 | Q4 | 259/333 |
| 2024 | ONCOLOGY | SCIE | Q4 | Q3 | 253/328 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q3 | 183/322 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q3 | 123/241 |
| 2021 | ONCOLOGY | SCIE | Q3 | Q3 | 145/245 |
| 2020 | ONCOLOGY | SCIE | Q4 | Q3 | 188/242 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q3 | 162/244 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q3 | 166/230 |
| 2016 | ONCOLOGY | SCIE | Q3 | — | 148/217 |
| 2015 | ONCOLOGY | SCIE | Q3 | — | 145/213 |
| 2014 | ONCOLOGY | SCIE | Q3 | — | 126/211 |
| 2013 | ONCOLOGY | SCIE | Q3 | — | 107/203 |
| 2012 | ONCOLOGY | SCIE | Q3 | — | 117/197 |
| 2011 | ONCOLOGY | SCIE | Q3 | — | 113/196 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 89/185 |
| 2009 | ONCOLOGY | SCIE | Q3 | — | 96/166 |
| 2008 | ONCOLOGY | SCIE | Q4 | — | 123/143 |
| 2007 | ONCOLOGY | SCIE | Q3 | — | 71/132 |
| 2006 | ONCOLOGY | SCIE | Q3 | — | 71/127 |
| 2005 | ONCOLOGY | SCIE | Q3 | — | 72/123 |
| 2004 | ONCOLOGY | SCIE | Q3 | — | 65/123 |
| 2003 | ONCOLOGY | SCIE | Q2 | — | 52/120 |
| 2002 | ONCOLOGY | SCIE | Q2 | — | 47/114 |
| 2001 | ONCOLOGY | SCIE | Q2 | — | 28/107 |
| 2000 | ONCOLOGY | SCIE | Q2 | — | 31/103 |
| 1999 | ONCOLOGY | SCIE | Q2 | — | 29/105 |
| 1998 | ONCOLOGY | SCIE | Q1 | — | 21/104 |
| 1997 | ONCOLOGY | SCIE | Q2 | — | 30/102 |